SCHEMBL4855640

SCHEMBL4855640

CC(C)(C)C([SiH2]Cl)(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
TSHR P16473 2/20 0.40
CYP2C19 P33261 1/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 3/20 0.38
TAAR1 Q96RJ0 1/20 0.38
ALOX15 P16050 1/20 0.38
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37
CYP3A4 P08684 1/20 0.37
KCNN4 O15554 3/20 0.36
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP1A2 P05177 1/20 0.33
CYP2B6 P20813 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11342153 0.75 MAPK1 (0.44) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL705506 0.75 MAPK1 (0.44) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL22730252 0.71 MAPK1 (0.41) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL6892052 0.70 TSHR (0.44) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL5167778 0.69 TSHR (0.48) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL10448326 0.68 CYP2C19 (0.41) MAPK1TSHRCYP2C19HIF1AALDH1A1
Tert-Butylbenzene SCHEMBL28464198 0.68 TSHR (0.53) MAPK1TSHRCYP2C19HIF1AALDH1A1
Tert-Butylbenzene SCHEMBL27713888 0.68 TSHR (0.53) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL10824244 0.67 TSHR (0.52) MAPK1TSHRCYP2C19HIF1AALDH1A1
SCHEMBL15275694 0.67 TSHR (0.52) MAPK1TSHRCYP2C19HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9562113-B2 Labeled alginate conjugates for molecular imaging applications BELLEROPHON BCM LLC (US) 2017-02-07 US disclosed
US-20160115252-A1 Labeled Alginate Conjugates For Molecular Imaging Applications IKARIA DEVELOPMENT SUBSIDIARY ONE LLC 2016-04-28 US disclosed
US-9260399-B2 Labeled alginate conjugates for molecular imaging applications BELLEROPHON BCM LLC (US) 2016-02-16 US disclosed
US-20150133645-A1 Labeled Alginate Conjugates For Molecular Imaging Applications IKARIA DEVELOPMENT SUBSIDIARY ONE LLC 2015-05-14 US disclosed
US-8974766-B2 Labeled alginate conjugates for molecular imaging applications BELLEROPHON BCM LLC (US) 2015-03-10 US disclosed
US-20130149242-A1 Labeled Alginate Conjugates for Molecular Imaging Applications IKARIA DEVELOPMENT SUBSIDIARY ONE LLC (US) 2013-06-13 US disclosed
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115252-A1 Labeled Alginate Conjugates For Molecular Imaging Applications ALG1, ALG8, ALG3 MAPK1 4661/4885TSHR 4161/4885CYP2C19 4858/4885
US-20150133645-A1 Labeled Alginate Conjugates For Molecular Imaging Applications ALG1, ALG8, ALG3 MAPK1 4661/4885TSHR 4161/4885CYP2C19 4858/4885
US-20130149242-A1 Labeled Alginate Conjugates for Molecular Imaging Applications ALG1, ALG8, ALG3 MAPK1 4661/4885TSHR 4161/4885CYP2C19 4858/4885
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 MAPK1 1445/4885TSHR 2067/4885CYP2C19 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.